Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.

You may also be interested in...



Thinking Long-Term, Novo Ventures Finds Itself On A Hot Streak Of Quick Exits

Despite a strategy that encourages holding stakes when other firms might sell, the evergreen fund has been generating quick returns.

Thinking Long-Term, Novo Ventures Finds Itself On A Hot Streak Of Quick Exits

Despite a strategy that encourages holding stakes when other firms might sell, the evergreen fund has been generating quick returns.

Novo Ventures' Hot Streak Of Exits

The evergreen fund is on a hot streak thanks to a recent string of exits.

Related Content

Topics

UsernamePublicRestriction

Register

PS070816

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel